Bainomugisa CK, Dasgupta P, Cameron JK, Tran B, Cramb SM, Baade PD. Spatial patterns of testicular cancer diagnosis in Australia, 2010-2019. Spatial and Spatio-temporal Epidemiology. 2025;55:10.1016/j.sste.2025.100745
Hiong A, Lynam J, Weickhardt A, Wong S, Sengupta S, Manohar P, Wong L, Dundee P, Lawrentschuk N, Zhang AY, Anton A, Raghunath A, Gibbs P, Tran B. Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia. BJUI Compass. 2025;6(9):10.1002/bco2.70083
Aziz NA, Ng K, Alifrangis C, Tran B, Conduit C, Liow E, Ackerman C, Georgescu R, Jamal T, Relton C, Mayer E, Nicol D, Cazzaniga W, Huddart R, Reid A, Shamash J, Rajan P. Therapy de‐escalation for testicular cancer (THERATEST): A multi‐centre observational cohort feasibility study of de‐escalation therapies for good prognosis stage II germ cell tumours. BJUI Compass. 2025;6(8):10.1002/bco2.70057
Furic L, Ferreira R, Hannan K, Kusnadi E, Panov K, George A, Huglo A, Lawrence M, Tran B, Desai J, Drygin D, Haddach M, Hein N, Hannan RD. 77P PMR-116, a second generation ribosome biogenesis inhibitor, displays antitumour activity in a wide range of preclinical cancer models and on-target activity in a phase I trial. ESMO Open. 2025;10:10.1016/j.esmoop.2025.105427
Moody SC, Fietz D, Nathaniel B, Frydenberg M, Tran B, Schuppe H, Loveland KL. Spatial transcriptomics mapping of immune cell and TGFβ signalling pathway heterogeneity in testicular germ cell tumours. Andrology. 2025;:10.1111/andr.70100
Conduit C, Bagrodia A, Hamilton RJ, Feldman DR, Tran B. Optimal Management of Stage II Seminoma: Preventing Harm While Preserving Cure.JCO Oncology Practice. 2025;:10.1200/op-25-00252
Williams C, Inderjeeth A-J, Hong W, McKenzie J, Anton A, Weickhardt A, Wong S, Shapiro J, Parente P, Goh J, Torres J, Smith A, Joshua A, Brown S, Steer C, Johns J, Gibbs P, Tran B, Azad AA. Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study. Clinical Genitourinary Cancer. 2025;23(3):10.1016/j.clgc.2025.102345
Weickhardt AJ, Foroudi F, Lawrentschuk N, Xie J, Ko Y-A, Sidhom M, Pal A, Grimison PS, Zhang AY, Ng S, Tang C, Hovey EJ, Chen C, Hruby G, Guminski AD, Oakes SR, Conduit C, Tran B, Davis ID, Hayne D. Pembrolizumab (pembro) with chemoradiotherapy (CRT) as treatment for muscle-invasive bladder cancer (MIBC): Long-term follow up of secondary endpoints of efficacy including overall survival of the PCR-MIB phase II clinical trial (ANZUP 1502).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.4577
Buteau JP, Kostos LK, Jackson P, McIntosh L, Alipour R, Akhurst TJ, Eifer M, Emmerson B, Haskali MB, Jewell K, Kashyap R, Kong G, Murphy D, Ravi Kumar AS, Saghebi J, Sandhu S, Tran B, Xie J, Azad A, Hofman MS. First-in-human results of terbium-161[ 161 Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.5010
Tran B, Spreafico A, Knapen DG, Oh D-Y, Hamilton E, Keenan BP, Khan SA, LoRusso P, Fakih M, Gordon M, Jing J, Liu Y, Holder P, Dogra P, Kirschbrown W, Shivva V, Tracy S, Monemi S, Sanjabi S, Ungewickell A, McCoach C, Kim TW. Abstract CT075: Phase 1a/1b dose-escalation study of efbalropendekin alfa (XmAb24306) as single-agent and with atezolizumab in solid tumors. Cancer Research. 2025;85(8_Supplement_2):10.1158/1538-7445.am2025-ct075
